News

AstraZeneca Unveils $50 Billion U.S. Investment Plan Amid Rising Tariff Pressures

The announcement aligns with a broader trend of pharmaceutical firms reshoring operations in response to U.S. political pressures. Trump has proposed giving companies a 12- to 18-month window to localize their production or face heavy duties—a policy aimed at ending America’s dependence on foreign drug supplies.

• By Newsdesk
• New Delhi
• Jul 22, 2025

News

In a major strategic shift, British pharmaceutical giant AstraZeneca has announced a $50 billion investment in the United States by 2030, marking one of the largest commitments by a global drugmaker to bolster American manufacturing and innovation. The move comes as former President Donald Trump signals plans to impose steep tariffs—potentially up to 200%—on drugs produced outside the U.S., intensifying pressure on foreign-based pharmaceutical companies.

Headquartered in Cambridge, UK, AstraZeneca said the investment will go toward a state-of-the-art manufacturing facility in Virginia and the expansion of its research, development, and cell therapy manufacturing capabilities across Maryland, Massachusetts, California, Indiana, and Texas.

The announcement aligns with a broader trend of pharmaceutical firms reshoring operations in response to U.S. political pressures. Trump has proposed giving companies a 12- to 18-month window to localize their production or face heavy duties—a policy aimed at ending America’s dependence on foreign drug supplies.

Howard Lutnick, U.S. Commerce Secretary, welcomed AstraZeneca’s decision, calling it a "historic investment" that would strengthen domestic supply chains and generate tens of thousands of American jobs. “We are proud AstraZeneca is bringing substantial pharmaceutical production to our shores. This ensures that medicines sold in our country are made right here at home,” he stated.

AstraZeneca CEO Pascal Soriot underscored that the investment supports the company’s goal of reaching $80 billion in revenue by 2030, with half of its sales projected to come from the U.S. The company reported $54.1 billion in revenue in 2024.

This move places AstraZeneca among a growing cohort of pharmaceutical giants accelerating U.S. investments. Swiss drugmaker Roche committed $50 billion to U.S. operations in April, pledging to create over 12,000 jobs. Novartis has outlined a $23 billion investment plan, while Johnson & Johnson announced a $55 billion boost to U.S. manufacturing and R&D in March.

The Trump administration has already initiated a probe into the pharmaceutical sector, citing concerns over national security and pricing practices related to foreign imports. In May, Trump criticized "profiteering" by pharmaceutical companies and vowed to end “price gouging from big pharma.”

Tech companies, too, are responding to the changing policy landscape. Apple revealed in February it would invest $500 billion in the U.S. over the next four years, including a massive AI server facility in Texas.

AstraZeneca’s U.S. expansion follows reports suggesting CEO Pascal Soriot may be considering relocating the company’s stock market listing from London to New York. Such a shift would be a significant setback for the UK’s financial markets, as AstraZeneca is among the FTSE 100’s largest constituents, with a market capitalization of £158.7 billion.